
Regulatory Meetings & Hearings
Upcoming meetings and hearings with regulatory agencies.
3 events · 3 companiesPublic 30-day window through Dec 21, 2026 (ET)
Scheduled catalysts
Next CatalystCompanyDrugPrice · 30DCurrent stage
NEONC TECHNOLOGIES HOLDINGS, INC.NTHI
DrugNEO212
Indication—three proposed parallel patient cohorts: brain metastases, IDH1-mutant astrocytoma and recurrent IDH1-wildtype glioblastoma
—
Program milestone
Price · 30D
$3.15+6.8%
30D · 11/20Biodexa Pharmaceuticals PlcBDRX
DrugMTX240
Indication—
—
Program milestone
Price · 30D
$1.88-43.4%
30D · 11/20VP
Vanda Pharmaceuticals Inc.VNDAIndicationJet lag disorder
Target · MT1 × MT2
US
a five-day hearing before the Administrative Law Judge from December 14, 2026 to December 18, 2026
SEC filingHighest reached · Phase 2
Price · 30D
$3.45-14.8%
30D · 11/20